Cover Image
市場調查報告書

顆粒球巨噬細胞群落刺激因子 (GM-CSF) :開發中產品分析

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 363578
出版日期 內容資訊 英文 106 Pages
訂單完成後即時交付
價格
Back to Top
顆粒球巨噬細胞群落刺激因子 (GM-CSF) :開發中產品分析 Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2018
出版日期: 2018年04月24日 內容資訊: 英文 106 Pages
簡介

本報告提供以顆粒球巨噬細胞群落刺激因子 (GM-CSF) 為標的之治療藥開發相關資訊,提供開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

顆粒球巨噬細胞群落刺激因子 (GM-CSF)的概要

治療藥的開發

  • 各開發階段
  • 各治療範圍
  • 各適應症
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Aduro BioTech Inc
  • Amgen Inc
  • BriaCell Therapeutics Corp
  • Cold Genesys Inc
  • GlaxoSmithKline Plc
  • Humabs BioMed SA
  • KaloBios Pharmaceuticals Inc
  • Morphotek Inc
  • Sillajen Biotherapeutics
  • 武田藥品工業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1436TDB

Summary:

According to the recently published report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2018'; Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) pipeline Target constitutes close to 20 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes.

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts. It stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes.

The report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2018' outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 9, 3, 3, 2 and 1 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Respiratory, Musculoskeletal Disorders and Undisclosed which include indications Breast Cancer, Rheumatoid Arthritis, Hepatocellular Carcinoma, Melanoma, Solid Tumor, Colorectal Cancer, Liver Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Liver Cancer, Multiple Sclerosis, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Renal Cell Carcinoma, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Anaplastic Large Cell Lymphoma (ALCL), Ankylosing Spondylitis (Bekhterev's Disease), Basal Cell Carcinoma (Basal Cell Epithelioma), Chronic Obstructive Pulmonary Disease (COPD), Colon Carcinoma, Cutaneous T-Cell Lymphoma, Extramammary Paget Disease (EMPD), Glioblastoma Multiforme (GBM), Juvenile Myelomonocytic Leukemia (JMML), Kidney Cancer (Renal Cell Cancer), Leukemias, Lung Adenocarcinoma, Lung Cancer, Lung Disease, Lymphoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Mycosis Fungoides, Natural Killer Cell Lymphomas, Neurotoxicity Syndromes, Nonmelanomatous Skin Cancer, Oral Cavity (Mouth) Cancer, Osteoarthritis Pain, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral T-Cell Lymphomas (PTCL), Prostate Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Sezary Syndrome and Unspecified.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
  • The report reviews Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Overview
    • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Companies Involved in Therapeutics Development
    • Aduro BioTech Inc
    • Amgen Inc
    • BriaCell Therapeutics Corp
    • Cold Genesys Inc
    • Epeius Biotechnologies Corp
    • GlaxoSmithKline Plc
    • Humanigen Inc
    • Izana Bioscience Ltd
    • Mologen AG
    • Morphotek Inc
    • Sillajen Biotherapeutics
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Drug Profiles
    • Bria-IMT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bria-OTS - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Activate CSF2 for Colorectal Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Activate GMCSF for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-0070 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-0070 + Immune Checkpoint Modulator - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gimsilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lenzilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGN-1601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Target GMCSF for Unspecified Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit GM-CSF for Immunological Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • namilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OrienX-010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • otilimab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pexastimogene devacirepvec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Reximmune-C2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBPL-0100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STINGVAX - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • talimogene laherparepvec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Dormant Products
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Discontinued Products
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 10, 2018: BriaCell to Present Encouraging Clinical Data at AACR 2018
      • Apr 03, 2018: BriaCell's Lead Product Candidate Mechanism of Action Described in a Major Immunology Journal
      • Mar 21, 2018: Targeted Immunotherapy Treatment Shows Promise for Treating Advanced Stage Liver Tumors
      • Mar 15, 2018: Humanigen Completes Enrollment of Phase 1 Clinical Trial of Lenzilumab for Treatment of Chronic Myelomonocytic Leukemia
      • Feb 23, 2018: SillaJen Poster Presentation at 2018 GU ASCO Symposium Highlights New Clinical Data in RCC, Intravenous Delivery of Pexa-Vec, Oncolytic Immunotherapy
      • Feb 13, 2018: Cancer-Killing Virus Acts by Alerting Immune System
      • Feb 06, 2018: BriaCell Opens Fourth Clinical Site in Advanced Breast Cancer
      • Feb 05, 2018: BriaCell Presenting at Upcoming Cancer Conference
      • Jan 31, 2018: BriaCell Update: Early Evidence of Efficacy and Safety of Bria-IMT
      • Jan 29, 2018: SillaJen Announces First Patient Enrolled in the NCI-Sponsored Trial Evaluating Combination Therapy in Colorectal Cancer with SillaJen's Pexa-Vec Oncolytic Immunotherapy
      • Jan 25, 2018: Humanigen CEO to Present at NobleCon14, BIO CEO Investor Conferences
      • Jan 03, 2018: BriaCell Provides Clinical Update on its Lead Immunotherapy Drug in Advanced Breast Cancer
      • Dec 14, 2017: Izana Bioscience Launches as New Clinical-Stage Translational Medicine Company Developing Namilumab in Ankylosing Spondylitis
      • Nov 06, 2017: BriaCell Provides Clinical Update on its Lead Vaccine Candidate, BriaVax
      • Oct 30, 2017: FDA Approves the Roll-Over Combination Study with Checkpoint Inhibitor Immunotherapies to Allow Continued Access to BriaVax in Patients with Advanced Breast Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Aduro BioTech Inc, H1 2018
  • Pipeline by Amgen Inc, H1 2018
  • Pipeline by BriaCell Therapeutics Corp, H1 2018
  • Pipeline by Cold Genesys Inc, H1 2018
  • Pipeline by Epeius Biotechnologies Corp, H1 2018
  • Pipeline by GlaxoSmithKline Plc, H1 2018
  • Pipeline by Humanigen Inc, H1 2018
  • Pipeline by Izana Bioscience Ltd, H1 2018
  • Pipeline by Mologen AG, H1 2018
  • Pipeline by Morphotek Inc, H1 2018
  • Pipeline by Sillajen Biotherapeutics, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top